Search

everythinglearnresearchcommunity

for

Search:↓

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Young women with PCOS have a higher risk of high blood pressure and metabolic syndrome, but these risks may decrease after age 40.

Irregular menstrual cycles in teenagers are linked to a higher risk of polycystic ovary syndrome and metabolic syndrome.

Excess male hormones in postmenopausal women can cause health issues and increase the risk of heart disease and diabetes; treatment depends on the cause.

Women with female pattern hair loss may have a higher risk of developing metabolic syndrome.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.

Human hair protein modifications could potentially indicate heart disease risk.

Finasteride lowers good cholesterol, raises bad fats, and may increase heart disease risk.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

Men with severe hair loss may have a higher risk of heart disease.

PCOS is a common hormonal disorder in women, often involving menstrual issues and increased diabetes risk, managed through lifestyle changes and targeted treatments.

The treatment successfully reopened blood flow in most patients and extended the use of their dialysis access with low risk.

Smoking harms the skin, causing early aging and increasing cancer risk, but stopping smoking can improve skin health.

Men with early hair loss have similar hormone levels to women with PCOS, possibly increasing risk of obesity and heart issues.

People with early onset baldness have higher bad cholesterol and lower good cholesterol, increasing their heart disease risk.

Substance abuse can cause various skin problems, including marks from injections, sores, premature aging, and increased cancer risk.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Acne can appear or persist in adulthood due to hormonal changes, external factors, or substance use, and requires appropriate treatment.

Treating psoriasis with UVB light three times a week is faster than twice a week, and certain medications and lifestyle factors affect psoriasis treatment outcomes.

Skin problems are common in Bangladesh due to arsenic, prompt treatment of diabetic foot ulcers is crucial, maternal transmission causes most neonatal herpes, treatments for pediatric vasculitis are effective, the chickenpox vaccine works, more frequent UVB therapy helps psoriasis, certain jobs increase hand dermatitis risk, monoclonal antibodies treat psoriasis well, lifestyle affects psoriasis, alefacept improves psoriasis, imiquimod cream partially clears basal cell carcinoma, and iron may not help chronic hair loss.

The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.

Men with common hair loss (AGA) are more likely to have metabolic syndrome, which increases heart disease risk. Early screening could help prevent heart disease. More research is needed to understand this relationship better.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Testosterone significantly affects sexual desire in both men and women, but its impact on women is more complex and influenced by psychological factors.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.